{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-035706","form_type":"8-K","ticker":"INBS","cik":"0001725430","company_name":"INTELLIGENT BIO SOLUTIONS INC.","filed_at":"2023-10-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.197879+00:00","generated_at":"2026-06-10T04:53:23.167158+00:00","sec_items":["1.01","5.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Intelligent Bio Solutions closes $4.38M public offering, net proceeds ~$3.35M","bullets":["Gross proceeds of $4.378M from offering of 2.23M common shares, 5.73M Series E preferred, and warrants to purchase up to 7.96M shares.","Net proceeds of approximately $3.35M after underwriting discounts and expenses, for general corporate purposes and working capital.","Series E Preferred Stock is convertible 1:1 into common stock, no dividend rights except as paid on common, limited voting rights.","CFO Spiro Sakiris purchased 112,727 Class A Units and director Christopher Towers purchased 9,090 Class A Units on same terms.","Underwriter's overallotment option partially exercised; warrants exercisable only after Nasdaq shareholder approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-035706","json":"https://secwatch.observer/filing/0001493152-23-035706.json","markdown":"https://secwatch.observer/filing/0001493152-23-035706.md","text":"https://secwatch.observer/filing/0001493152-23-035706.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725430/000149315223035706/0001493152-23-035706-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725430/000149315223035706/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T04:53:23.167158+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9907c9819a97cdf652dc936e1a6acd5b87adc36e","claim":"INTELLIGENT BIO SOLUTIONS INC.: Filed Certificate of Designation for Series E Convertible Preferred Stock, designating 5,728,723 shares of Series E Preferred Stock, with no voting rights, convertible into common stock, and no dividends unless declared by the board (effective 2023-10-03).","evidence_excerpt":"In connection with the Public Offering, the Company filed the Certificate of Designation of Preferences, Rights and Limitations of the Series E Convertible Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Delaware on October 3, 2023.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1725430/000149315223035706/0001493152-23-035706-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-10-03"}],"fact_type":"governance_change"},{"claim_id":"4cb786ce7ea8981975ef9802c7002300523949a7","claim":"INTELLIGENT BIO SOLUTIONS INC. entered into Underwriting Agreement with Ladenburg Thalmann & Co. Inc. (effective 2023-10-02).","evidence_excerpt":"On October 2, 2023, Intelligent Bio Solutions Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Ladenburg Thalmann & Co. Inc., as representative (the “Representative”) of the underwriters named in Schedule I thereto (collectively, the “Underwriters”), pursuant to which the Company agreed to issue and sell, in a registered public offering by the Company (the “Public Offering”): (a) 1,544,004 Class A Units","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1725430/000149315223035706/0001493152-23-035706-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Ladenburg Thalmann & Co. Inc."},{"label":"Effective","value":"2023-10-02"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}